Analysts Offer Predictions for ASND FY2026 Earnings

Ascendis Pharma A/S (NASDAQ:ASND - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for Ascendis Pharma A/S in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst L. Watsek anticipates that the biotechnology company will post earnings per share of $3.43 for the year. Cantor Fitzgerald has a "Overweight" rating and a $200.00 price target on the stock. The consensus estimate for Ascendis Pharma A/S's current full-year earnings is ($4.34) per share.

Other analysts have also issued research reports about the company. Morgan Stanley upgraded Ascendis Pharma A/S from an "equal weight" rating to an "overweight" rating and increased their price target for the company from $180.00 to $250.00 in a report on Monday, May 5th. Royal Bank of Canada raised their price objective on Ascendis Pharma A/S from $205.00 to $210.00 and gave the company an "outperform" rating in a research report on Friday, May 2nd. JPMorgan Chase & Co. lifted their target price on shares of Ascendis Pharma A/S from $200.00 to $245.00 and gave the stock an "overweight" rating in a research note on Friday, May 2nd. The Goldman Sachs Group upped their price objective on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a "buy" rating in a report on Thursday, February 13th. Finally, Wedbush lifted their target price on shares of Ascendis Pharma A/S from $181.00 to $212.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. One analyst has rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $217.73.

Ascendis Pharma A/S Stock Down 0.4%

ASND stock traded down $0.63 during midday trading on Tuesday, hitting $171.72. The company's stock had a trading volume of 231,952 shares, compared to its average volume of 494,581. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $183.00. The firm has a market capitalization of $10.49 billion, a price-to-earnings ratio of -24.19 and a beta of 0.37. The company has a 50 day moving average of $160.40 and a two-hundred day moving average of $147.45.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The firm had revenue of $123.97 million for the quarter, compared to analyst estimates of $98.56 million.

Hedge Funds Weigh In On Ascendis Pharma A/S

Several hedge funds and other institutional investors have recently bought and sold shares of ASND. Aristeia Capital L.L.C. increased its holdings in shares of Ascendis Pharma A/S by 4.6% in the 1st quarter. Aristeia Capital L.L.C. now owns 11,300 shares of the biotechnology company's stock valued at $1,761,000 after acquiring an additional 500 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Ascendis Pharma A/S by 10.4% in the first quarter. Goldman Sachs Group Inc. now owns 585,581 shares of the biotechnology company's stock valued at $91,269,000 after buying an additional 55,164 shares during the period. Cinctive Capital Management LP acquired a new stake in shares of Ascendis Pharma A/S during the first quarter worth $1,191,000. Advisors Asset Management Inc. raised its position in Ascendis Pharma A/S by 11.5% during the first quarter. Advisors Asset Management Inc. now owns 9,190 shares of the biotechnology company's stock valued at $1,432,000 after buying an additional 949 shares during the period. Finally, Adage Capital Partners GP L.L.C. acquired a new position in Ascendis Pharma A/S during the first quarter valued at $51,029,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.